section name header

Pronunciation

a-bem-a-SYE-klib

Classifications

Therapeutic Classification: antineoplastics

Pharmacologic Classification: kinase inhibitors

Indications

High Alert

Action

Therapeutic Effects:

Pharmacokinetics

Absorption: 45% absorbed following oral administration.

Distribution: Extensively distributed to tissues.

Protein Binding: 96%.

Metabolism/Excretion: Primarily metabolized in the liver by CYP3A4 to several active metabolites; 81% excreted in feces, 3% in urine.

Half-life: 18.3 hr.

Time/Action Profile

(blood levels)

ROUTEONSETPEAKDURATION
POunknown8 hr24 hr

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: peripheral edema, VENOUS THROMBOEMBOLISM.

Derm: alopecia, pruritus, rash.

GI: appetite, liver enzymes, abdominal pain, constipation, diarrhea, dry mouth, nausea, stomatitis, vomiting, HEPATOTOXICITY.

GU: serum creatinine, fertility (males).

Hemat: anemia, leukopenia, neutropenia, thrombocytopenia.

Metab: weight.

MS: arthralgia.

Neuro: dizziness, dysgeusia, fatigue, headache.

Resp: cough, INTERSTITIAL LUNG DISEASE/PNEUMONITIS.
Misc: fever, infection.

Interactions

Drug-Drug:

Route/Dosage

Hepatic Impairment

Availability

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Verzenio